alexa Prognostic significance of MDM2 gene expression in childhood neuroblastoma.
Genetics & Molecular Biology

Genetics & Molecular Biology

Hereditary Genetics: Current Research

Author(s): Inomistova MV, Svergun NM, Khranovska NM, Skachkova OV, Gorbach OI,

Abstract Share this page

Abstract AIM: To investigate the association of MDM2 expression at the mRNA levels in neuroblastoma with clinical features and unfavorable disease factors to determine the possibility of it usage as a prognostic marker of neuroblastoma. MATERIALS AND METHODS: Total RNA and DNA were extracted from tumor tissue samples of total 91 neuroblastoma patients (mean age: 39.45 ± 4.81 months). MDM2 mRNA levels were detected with Q-PCR. TP53 gene deletion was detected with FISH method. MYCN amplification was detected with -Q-PCR analysis in fresh tumor samples and FISH in FFPE samples. RESULTS: We investigated the association of MDM2 mRNA expression with clinical outcome in neuroblastoma patients (n = 91). Kaplan - Meier curves showed a significant association of high MDM2 expression with poor event-free survival (p < 0.001). Clinical outcome of patients without MYCN amplification with low MDM2 expression was associated with better event-free survival than with high MDM2 expression (p < 0.001). Overexpression of MDM2 can be used as significant prognostic marker for patient stratification on risk groups and treatment optimization. CONCLUSION: Our results showed that the high expression of MDM2 at mRNA levels is an important factor of neuroblastoma prognosis. It may be a valuable additional molecular marker in guiding specific therapy in MYCN non-amplified NB patients without TP53 gene deletion.
This article was published in Exp Oncol and referenced in Hereditary Genetics: Current Research

Relevant Expert PPTs

Relevant Speaker PPTs

  • Rajeev Taggar
    The application of plant biotechnology in seed industry in the developing countries
    PPT Version | PDF Version
  • Alla Ovsyannikova
    MODY 2 diabetes in Siberia: 3 years of follow up
    PPT Version | PDF Version
  • Lydiya Thomas
    he use of the Problem Areas In Diabetes (PAID) scale amongst patients with Type 2 diabetes
    PPT Version | PDF Version
  • Rachel Knott
    The role of oxygen insufficiency in the onset and development of the vascular complications of diabetes
    PPT Version | PDF Version
  • David T Denhardt
    Epigenetics and sports medicine
    PPT Version | PDF Version
  • Ganapathi Bhat Mugulthimoole
    Unmasking the masquerading cancer cells: have we made progress with the revival of immunotherapy?
    PPT Version | PDF Version
  • Dwi Astuti
    Phylogenetic position of Psittacula parakeet bird from Enggano Island, Indonesia based on analyses of cytochrome b gene sequences
    PPT Version | PDF Version
  • Shree Kumar Apte
    Genetic engineering of Deinococcus radiodurans for uranium bioremediation from high radiation environment
    PPT Version | PDF Version
  • Julian M Menter
    Histology of Normal Human Skin
    PPT Version | PDF Version
  • San Ming Wang
    Unknown genetic predisposition in familial breast cancer can lie deep in family tree
    PPT Version | PDF Version
  • Jan Scicinski
    RRx-001, a novel ROS-mediated epigenetic modulator: ‘Episensitization’ to previously failed therapies
    PPT Version | PDF Version
  • Erkan Orman
    Erkan-Orman-Anadolu-University-Turkey-Shape-optimization-of-a-wind-turbine-airfoil-by-using-genetic-algorithm
    PPT Version | PDF Version
  • Yosef Yarden
    Classically, the 3’untranslated region (3’UTR) is that region in eukaryotic protein-coding genes from the translation termination codon to the polyA signal. It is transcribed as an integral part of the mRNA encoded by the gene. However, there exists another kind of RNA, which consists of the 3’UTR alone, without all other elements in mRNA such as 5’UTR and coding region. The importance of independent 3’UTR RNA (referred as I3’UTR) was prompted by results of artificially introducing such RNA species into malignant mammalian cells. Since 1991, we found that the middle part of the 3’UTR of the human nuclear factor for interleukin-6 (NF-IL6) or C/EBP gene exerted tumor suppression effect in vivo. Our subsequent studies showed that transfection of C/EBP 3’UTR led to down-regulation of several genes favorable for malignancy and to up-regulation of some genes favorable for phenotypic reversion. Also, it was shown that the sequences near the termini of the C/EBP 3’UTR were important for its tumor suppression activity. Then, the C/EBP 3’UTR was found to directly inhibit the phosphorylation activity of protein kinase CPKC in SMMC-7721, a hepatocarcinoma cell line. Recently, an AU-rich region in the C/EBP 3’UTR was found also to be responsible for its tumor suppression. Recently we have also found evidence that the independent C/EBP 3’UTR RNA is actually exists in human tissues, such as fetal liver and heart, pregnant uterus, senescent fibroblasts etc. Through 1990’s to 2000’s, world scientists found several 3’UTR RNAs that functioned as artificial independent RNAs in cancer cells and resulted in tumor suppression. Interestingly, majority of genes for these RNAs have promoter-like structures in their 3’UTR regions, although the existence of their transcribed products as independent 3’UTR RNAs is still to be confirmed. Our studies indicate that the independent 3’UTR RNA is a novel non-coding RNA species whose function should be the regulation not of the expression of their original mRNA, but of some essential life activities of the cell as a whole.
    PPT Version | PDF Version
  • Galya Naydenova Atanasova
    Genetic Markers of Coronary Artery Disease Risk
    PPT Version | PDF Version
  • Mark A. Skinner
    Mark-A-Skinner-The-Boeing-Company-USA-Orbital-debris-What-are-the-best-near-term-actions-to-take-a view-from-the-field
    PPT Version | PDF Version

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords